Actively Recruiting
Asian Myeloproliferative Neoplasm (MPN) Registry - An Asian Myeloid Working Group (AMWG) Project.
Led by The University of Hong Kong · Updated on 2023-05-31
1000
Participants Needed
1
Research Sites
30 weeks
Total Duration
On this page
Sponsors
T
The University of Hong Kong
Lead Sponsor
N
Novartis
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are conducting a multinational, multicenter observational study to collect detailed information on patients with myeloproliferative neoplasms (MPN) from Asia. This registry includes patients diagnosed between 2010 and 2025 and aims to gather data on clinical features, genetic characteristics, treatments, outcomes, and survival of these patients. The study involves centers in various Asian countries, including Hong Kong, Singapore, Malaysia, Taiwan, Korea, and Thailand. The study collects information both retrospectively and prospectively through routine clinic visits and medical record reviews. Data are gathered at diagnosis and approximately every six months thereafter, continuing until disease progression, death, or study conclusion. The main focus is on tracking disease progression to secondary myelofibrosis, progression-free survival, and overall survival over a ten-year period. Participants will be monitored through their regular medical appointments, with data collected on their disease status, treatment responses, and survival outcomes. Researchers will analyze this information to better understand MPN characteristics and outcomes among Asian patients. The observation period lasts up to ten years, providing long-term insights into the disease course and treatment effects.
CONDITIONS
Brief Title
Asian Myeloproliferative Neoplasm (MPN) Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at the time of diagnosis of MPN
- Diagnosis of one of the following according to 2017 WHO classification: Polycythaemia vera, Essential thrombocythemia, Primary myelofibrosis (pre-fibrotic or overt fibrotic stage), Post-polycythaemia vera myelofibrosis, Post-essential thrombocythemia myelofibrosis, or MPN-unclassifiable
- Ability to provide informed consent
You will not qualify if you...
- Diagnosis of myelodysplastic syndrome
- Diagnosis of myelodysplastic syndrome/myeloproliferative neoplasm
- Diagnosis of chronic myeloid leukemia BCR-ABL1 positive according to 2017 WHO classification
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 15 years
Participants who undergo routine care are observed, with data collected from diagnosis and approximately every 6 months thereafter, as well as at disease progression until death or study end.
Visits approximately every 6 months and at disease progression
Trial Site Locations
Total: 1 location
1
Department of Medicine, Queen Mary Hospital
Hong Kong, Hong Kong
Actively Recruiting
Research Team
H
Harinder Gill, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here